-Board approves for the allotment of 210 955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.

-Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route.

-Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act.

-Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200 000 as 100% wholly owned subsidiary.

-Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations.

2003

-Nominates Mr Francis Pinto as the Director on the Board of the company.

-Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare mainly to share the product development expertise and quality systems.

-Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics OTC and Nutraceutical products.

-Changes in the Management:Appoints Mr V Hariharan as CFO Mr Joe Thomas as President and Mr Krishna Kumar Menon as COO.

-Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company.

-Strides inks MoU with Ribbon SRL for Cephalosporin

2004

-Major Fire occurs in Private Custom Bonded warehouse in Mexico

-Strides Arcolab Limited has entered into a memorandum of understanding with BITS Pilani for an ``off campus collaborative programme'. As part of the partnership Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job.

2005

- Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets.

-Strides Arcolab enters into an agreement for private placement issue

- Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs

-Strides acquires sterile manufacturing facility in Poland

2007

- Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets an anti-HIV drug. Efavirenz is the generic version of Bristol Myers Squibb's Sustiva which helps in preventing the HIV virus from reproduction.- Strides Arcolab receives 2 more NDA approvals from US-FDA.

2008